Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CollPlant Biotechnologies (CLGN) Capital Expenditures (2018 - 2025)

Historic Capital Expenditures for CollPlant Biotechnologies (CLGN) over the last 8 years, with Q3 2025 value amounting to -$1000.0.

  • CollPlant Biotechnologies' Capital Expenditures rose 9928.57% to -$1000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$72000.0, marking a year-over-year increase of 8897.4%. This contributed to the annual value of -$483000.0 for FY2024, which is 4937.11% up from last year.
  • Per CollPlant Biotechnologies' latest filing, its Capital Expenditures stood at -$1000.0 for Q3 2025, which was up 9928.57% from -$3000.0 recorded in Q2 2025.
  • CollPlant Biotechnologies' 5-year Capital Expenditures high stood at -$1000.0 for Q3 2025, and its period low was -$1.4 million during Q4 2021.
  • Over the past 5 years, CollPlant Biotechnologies' median Capital Expenditures value was -$229000.0 (recorded in 2023), while the average stood at -$321526.3.
  • Its Capital Expenditures has fluctuated over the past 5 years, first tumbled by 60348.84% in 2021, then skyrocketed by 9928.57% in 2025.
  • Quarter analysis of 5 years shows CollPlant Biotechnologies' Capital Expenditures stood at -$1.4 million in 2021, then rose by 10.78% to -$1.3 million in 2022, then surged by 82.03% to -$229000.0 in 2023, then surged by 74.24% to -$59000.0 in 2024, then surged by 98.31% to -$1000.0 in 2025.
  • Its Capital Expenditures stands at -$1000.0 for Q3 2025, versus -$3000.0 for Q2 2025 and -$9000.0 for Q1 2025.